Archive for December, 2009
Vulval Cancer Treatment
Radiotherapy
Radiotherapy is used for the treatment of the cancer by employing high-power energy rays for killing the cancer cells while causing negligible damage to the healthy cells. Radiotherapy for vulval cancer could be administered either externally or internally or a merger of the two ways.
There are numerous means of administering radiotherapy for vulval cancer treatment. It could be done prior to surgery for attempting to shrivel the cancer and for making a smaller-scaled surgery possible. Radiotherapy could additionally be offered subsequent to surgery in case the cancer has not been totally eradicated or in case there is cancer present in the lymph nodes.
Radiotherapy is prevalently employed for vulval cancer treatment that has recurred or metastasized. In case the cancer is present [...]
December 9th, 2009 |
Vulval Cancer
Smoking Related To Increased Risk Of Developing Colorectal Cancer
A new-fangled study re-enforces the facts that those who indulged in cigarette smoking over protracted periods of time had a greater likelihood of developing colorectal cancer, despite adjustment of other risk factors.
Michael J. Thun, M.D., M.S., the senior author of the study, the vice president of emeritus, epidemiology and surveillance research at the American Cancer Society stated that colorectal cancer needs to be included in the long listing of cancers that arise as an outcome of cigarette smoking.
The findings have been printed in the December edition of ‘Cancer Epidemiology, Biomarkers & Prevention- a medical journal of the American Association For Cancer Research as part of a singular spotlight on tobacco.
Thun and his associates analysed the relationship in between long-standing [...]
December 8th, 2009 |
Colorectal Cancer
Rhabdomyosarcoma Staging And Treatment
Rhabdomyosarcoma is a form of childhood cancer constituting 5-8% of all detected cancers among infants. It originates in the cells that would develop into skeletal muscle cells. Skeletal muscle attached to the bones is diverse from the smooth muscles that are found in the lining of the intestinal tract. The uninhibited growth of these muscle cells leads to the formation of masses or lumps known as tumors. This form of unrestrained growth could begin in any part of the body where skeletal muscle is present, though prevalently detected in the head and neck, prostate, bladder and vagina.
Rhabdomyosarcoma is commonly seen in infants aged between two to six years and in between fifteen to nineteen years. The male gender is observed to be affected more than females. In younger kids, the tumor is [...]
December 8th, 2009 |
Childhood Cancers
Crucial Atoh1 Gene Identification That Incites Lethal Brain Cancer
Researchers from the HHMI or Howard Hughes Medical Institute have detected a novel factor that is indispensable for the development of several kinds of medulloblastoma – the prevalent form of malignant childhood brain cancer.
HHMI researcher Huda Y. Zoghbi and associates from Baylor College Of Medicine averted development of medulloblastoma among mice by impeding the manufacture of the Atoh1 protein in vulnerable brain cells. The findings of the research team were cited in the 4th December 2009 edition of ‘Science’ indicate that Atoh1 might be a novel target in treating medulloblastoma.
Zoghbi explicated that they didn’t have the faintest clue about the significance of the Atoh1 gene when they carried out its cloning way back in 1996. Presently it is known that it is important for several [...]
December 7th, 2009 |
Brain Cancer
Elastrography Lowers Redundant Breast Biopsies
According to an in-progress study presented during the yearly congregation of the Radiological Society of North America (RSNA) showed that elastography is an effectual, expedient system that when included to breast ultrasound aids in detection of cancerous breast lesions from benign outcomes.
When the outcome of mammography gives dubious findings, doctors mostly employ ultrasound to attain added information. On the other hand ultrasound has the possibility to lead to additional biopsies due to its comparatively squat specificity or incapability to precisely differentiate cancerous lesions from benign lesions. According to the American Cancer Society about eighty percent of breast lesions that underwent biopsies turned out to be benign in nature.
Stamatia V. Destounis, M.D., the lead author [...]
December 7th, 2009 |
Breast Cancer
Liver Cancer
Liver Cancer that is either primary or secondary cancer involves the uninhibited growth of cells. The risk of developing liver cancer is the highest among those having long lasting infection of hepatitis B, advanced stages of hepatitis C and liver cirrhosis. Due to the prevalence of hepatitis viruses, liver cancer is the second universal reason behind fatalities.
Particular heritable conditions additionally make one more inclined to developing liver cancer inclusive of tyrosinemia among infants, an atypical disorder that arises due to the body’s incapability of effectually breaking down tyrosine – an amino acid and uncured hemochromatosis – a disorder affecting adults that leads to the body absorbing and storing excessive amounts of iron. Chronic liver inflammation and wound are widespread [...]
December 7th, 2009 |
Liver Cancer
Fine-Tuning Breast Cancer Screening Employing DOT
Scientists from Clemson University in association with scientists from the University of Bremen, Germany are working in unison to allay the physical discomforting sensation undergone during mammograms a matter of the past, and allowing for investigative imaging to be ultimately carried out in a house setting.
The group of scientists are aiming at refining DOT or Diffuse Optical Tomography for creating enhanced resolution imagery from a diffusion of infrared and detectable light for the early diagnosis of breast cancer. The procedure is cost-effective, has a higher safety quotient and less levels of discomfort associated with it in comparison to the X-rays that have been employed during mammograms. The issue with X-rays is producing an effective resolution for detecting smaller breast cancers.
The [...]
December 4th, 2009 |
Breast Cancer
Copper-Impounding Drug TM Effectual As Cancer-Combatant Drug
The copper-confiscating drug TM or tetrathiomolybdate has been observed to be effectual in treating Wilson’s disease – a disease that occurs due to a surplus of copper and some forms of metastatic cancers. However, there is dearth of knowledge regarding how the drug functions at the molecular levels.
A new-fangled study carried out by researchers from the North-western University presently have been able to provide an important inkling- the 3-D make-up of TM joined to copper-laden metallochaperones. The drug impounds the chaperone and its joint copper, averting the duo from performing their usual tasks in the cell. This would prove to be immensely beneficial for those patients having Wilson’s disease and particular forms of cancers whose original proliferation is aided by copper-dependent [...]
December 4th, 2009 |
News
Gene UGT2B17 – Major Contributor To Bone Marrow Transplant Success Rate
A generally heritable gene erasure could raise the probability of immune complications subsequent to bone marrow transplantation, a global team of scientists reported in the 22nd November advance online issue of the journal ‘Nature Genetics’. When the gene known as UGT2B17 is absent in the donor’s genome, but there in the receiver’s genome, transplants have a radically increased risk of grave side effect called the graft-versus-host disease wherein the immune cells present in the donor lays assault on the tissues present in the receiver.
Steven McCarroll, first author cum asst. Professor from Harvard Medical School, an associate member from the Broad Institute of MIT and Harvard who directed the study when functioning as a postdoctoral member with David Altshuler in Masachusetts General [...]
December 4th, 2009 |
News
Doubled Survival Rates For High Risk (Ph+ALL) Leukemia With Novel Imatinib Treatment
Outcomes of the Phase II clinical trials printed in the 5th October edition of the Journal of Clinical Oncology reveals that including continual every day dosages of the targeted drug known as imatinib mesylate to standard chemotherapy showed a greater than two folds rise in survival rates in infants having a high risk form of blood cancer known as Philadephia chromosome-positive acute lymphoblastic leukemia or Ph+ALL thus proving to be a path-breaking revelation in the field of leukemia research.
The Children’s Oncology Group conducted the study in about twenty N. American centres helmed by Dr. Kirk Schultz, who heads the childhood cancer research at the Child & Family Research Institute (CFRI) and a paediatric oncologist from the BC Children’s Hospital, an agency of the Provincial [...]
December 3rd, 2009 |
News
Development Of Nano-Level Cancer Combatant Drug For Chemotherapy
Cancer combatant drugs just shrunk in size, though possessing more potency and providing enhanced outcomes.
Bioengineers from the Duke University have evolved a simplistic and cost-effectual means to load cancer drug consignments into nano-level release mediums and exhibited in animal models that this novel nano-formulation could eradicate tumors following a solo treatment. Subsequent to conveying the drug to the tumor, the delivery medium disperses into undamaging by-products, thus distinctly lowering the toxicity for the receiver.
Nano-release systems are turning out to be progressively more eye-catching to scientists due to their capacity of effectually getting within the tumors. Due to the permeable nature of the blood vessels that supply the tumors as compared to the normal vessels, the [...]
December 2nd, 2009 |
News
Study Indicates No Overuse Of Mastectomies In Breast Cancer Treatments
There have been growing fears about mastectomy being overly employed as a treatment option for breast cancer. A study conducted that was printed in the 14th October edition of JAMA, carried out an analysis of about two thousand women suggested that breast-conservation surgery was undertaken as the initial treatment in nearly 75% of those analysed.
Monica Morrow, M.D., from the Memorial Sloan-Kettering Cancer Center, New York did the presentation of the study findings at the JAMA media update in Chicago. She stated that the rising worries of mastectomy being used on patients having breast cancer have increased in past twenty years. BCS or breast conservation surgery has been employed by few as a quality measure. In spite of a noticeable rise in BCS, fears continue about the overtreatment with [...]
December 2nd, 2009 |
Breast Cancer
